The defective mucociliary clearance due to CFTR malfunctioning causes predisposition to the colonization of pathogens responsible for the recurrent inflammation and rapid deterioration of lung function in patients with cystic fibrosis (CF). This has also a profound effect on the lung microbiome composition, causing a progressive reduction in its diversity, which has become a common characteristic of patients affected by CF. Although we know that the lung microbiome plays an essential role in maintaining lung physiology, our comprehension of how the microbial components interact with each other and the lung, as well as how these interactions change during the disease’s course, is still at an early stage. Many challenges exist and many questions still to be answered, but there is no doubt that manipulation of the lung microbiome could help to develop better therapies for people affected by CF.

Lung microbiome in cystic fibrosis / Scialo, F.; Amato, F.; Cernera, G.; Gelzo, M.; Zarrilli, F.; Comegna, M.; Pastore, L.; Bianco, A.; Castaldo, G.. - In: LIFE. - ISSN 2075-1729. - 11:2 Article number 94(2021), pp. 1-7. [10.3390/life11020094]

Lung microbiome in cystic fibrosis

Amato F.;Cernera G.;Gelzo M.;Zarrilli F.;Comegna M.;Pastore L.;Castaldo G.
2021

Abstract

The defective mucociliary clearance due to CFTR malfunctioning causes predisposition to the colonization of pathogens responsible for the recurrent inflammation and rapid deterioration of lung function in patients with cystic fibrosis (CF). This has also a profound effect on the lung microbiome composition, causing a progressive reduction in its diversity, which has become a common characteristic of patients affected by CF. Although we know that the lung microbiome plays an essential role in maintaining lung physiology, our comprehension of how the microbial components interact with each other and the lung, as well as how these interactions change during the disease’s course, is still at an early stage. Many challenges exist and many questions still to be answered, but there is no doubt that manipulation of the lung microbiome could help to develop better therapies for people affected by CF.
2021
Lung microbiome in cystic fibrosis / Scialo, F.; Amato, F.; Cernera, G.; Gelzo, M.; Zarrilli, F.; Comegna, M.; Pastore, L.; Bianco, A.; Castaldo, G.. - In: LIFE. - ISSN 2075-1729. - 11:2 Article number 94(2021), pp. 1-7. [10.3390/life11020094]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/839887
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact